



Siliq in Jordan

The JFDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · IL-17 RECEPTOR A

The clinical situation

Siliq (brodalumab) is an FDA-approved fully human monoclonal antibody to IL-17 receptor A indicated for moderate-to-severe plaque psoriasis in adults who have failed other systemic therapy. Manufactured by Bausch Health/Valeant (formerly Valeant Pharmaceuticals). Standard dosing is 210 mg SC at weeks 0, 1, and 2, then every 2 weeks; refrigerated storage 2-8°C, pre-filled syringe. Carries a boxed warning for suicidal ideation and behaviour and is available only through a REMS programme in the US.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist documents psoriasis severity, prior biologic failure, psychiatric history (given the boxed warning), and TB/HBV/HCV screening.
- 2 Treating centre confirmed.** A Jordanian tertiary dermatology centre in Amman accepts the case with the risk-management plan documented.
- 3 JFDA named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed with the JFDA unregistered drug committee.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; temperature-monitored 2-8°C shipment.
- 5 Arrival & administration.** Patient self-administers SC with psychiatric screening prior to each dose per risk-management plan; PASI/BSA reassessed at 12-16 weeks.

Indicative economics

Reference US cash-pay range: USD 3,800–4,500 per 2-week dose. JFDA documentation, cold-chain logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete JFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and JFDA review. **Logistics.** Temperature-monitored cold-chain shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating dermatologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Siliq × Jordan first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/siliq-jordan.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team